Phio Pharmaceuticals Corp. 8-K

What Happened

• On February 10, 2026, Phio Pharmaceuticals (PHIO) issued a press release (filed as Exhibit 99.1 in an 8‑K) announcing that the trial Safety Medical Committee (SMC) reached a formal conclusion regarding the Company’s Phase 1b clinical trial of PH‑762. The company also provided updates on the trial’s response rates in that release.

Key Details

• Filing date: February 10, 2026 (Form 8‑K, Item 8.01 — Other Events).
• Program: PH‑762, Phase 1b clinical trial.
• Action: Safety Medical Committee issued a formal conclusion and the company updated response‑rate information.
• Press release attached as Exhibit 99.1 to the 8‑K for full details.

Why It Matters

• A Safety Medical Committee conclusion is a material clinical-development event that can affect trial continuation, next steps in development, and investor expectations.
• Updated response rates provide new data points about PH‑762’s activity that investors may use to reassess the program’s clinical progress.
• Investors should read the full press release (Exhibit 99.1) and watch for further company disclosures for specifics on the SMC conclusion, detailed response‑rate numbers, and any implications for timelines or strategy.